Drug Trial Radar · NCT06703177
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
876
Planned (sponsor's estimate)
Start
Feb 18, 2025
Primary completion
Jan 1, 2026
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SHR-1826Drug
SHR-1826
SHR-4642Drug
SHR-4642
SHR-9839Drug
SHR-9839
SHR-8068Drug
SHR-8068
Bevacizumab InjectionDrug
Bevacizumab Injection
Fluorouracil InjectionDrug
Fluorouracil Injection
Calcium Folinate InjectionDrug
Calcium Folinate Injection
Adebrelimab InjectionDrug
Adebrelimab Injection
Capecitabine tabletsDrug
Capecitabine tablets, oral.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RP2D (Phase 1)Time frame: Screening up to study completion, an average of 1 year.
- AE (Phase 1)Time frame: Screening up to study completion, an average of 1 year.
- Objective response rate (ORR) (Phase 2)Time frame: Screening up to study completion, an average of 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-Sen university cancer center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.